DF Dent & Co. Inc. grew its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 438.2% in the third quarter, according to its most recent filing with the SEC. The firm owned 75,856 shares of the medical device company’s stock after acquiring an additional 61,762 shares during the quarter. DF Dent & Co. Inc. owned about 0.09% of DexCom worth $3,711,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. World Asset Management Inc raised its stake in shares of DexCom by 4.1% in the 2nd quarter. World Asset Management Inc now owns 3,901 shares of the medical device company’s stock worth $285,000 after buying an additional 155 shares in the last quarter. Rathbone Brothers plc raised its stake in shares of DexCom by 5.3% in the 2nd quarter. Rathbone Brothers plc now owns 4,000 shares of the medical device company’s stock worth $293,000 after buying an additional 200 shares in the last quarter. Wedbush Securities Inc. raised its stake in shares of DexCom by 5.0% in the 2nd quarter. Wedbush Securities Inc. now owns 4,200 shares of the medical device company’s stock worth $307,000 after buying an additional 200 shares in the last quarter. Janney Montgomery Scott LLC raised its stake in shares of DexCom by 9.2% in the 2nd quarter. Janney Montgomery Scott LLC now owns 2,959 shares of the medical device company’s stock worth $216,000 after buying an additional 250 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in shares of DexCom by 12.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,254 shares of the medical device company’s stock worth $238,000 after buying an additional 354 shares in the last quarter.

A number of research firms have recently commented on DXCM. BidaskClub raised DexCom from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. BMO Capital Markets boosted their price objective on DexCom to $74.00 and gave the stock an “outperform” rating in a research note on Tuesday. Wedbush reissued an “outperform” rating and issued a $76.00 price objective (down previously from $85.00) on shares of DexCom in a research note on Thursday, September 28th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $78.00 target price (down from $87.00) on shares of DexCom in a research report on Wednesday, August 16th. Finally, Northland Securities lowered DexCom from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $85.00 to $60.00 in a research report on Thursday, September 28th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $71.36.

In related news, EVP Andrew K. Balo sold 6,490 shares of the company’s stock in a transaction on Wednesday, November 29th. The stock was sold at an average price of $60.00, for a total transaction of $389,400.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 6,000 shares of the company’s stock in a transaction on Wednesday, September 20th. The shares were sold at an average price of $69.34, for a total value of $416,040.00. The disclosure for this sale can be found here. Insiders have sold 34,710 shares of company stock worth $2,031,852 over the last three months. 1.70% of the stock is owned by insiders.

Shares of DexCom, Inc. (NASDAQ:DXCM) opened at $57.25 on Wednesday. The company has a debt-to-equity ratio of 0.84, a quick ratio of 5.50 and a current ratio of 5.86. DexCom, Inc. has a 52-week low of $42.62 and a 52-week high of $88.80.

TRADEMARK VIOLATION NOTICE: This story was first reported by Watch List News and is the property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://www.watchlistnews.com/df-dent-co-inc-has-3-71-million-holdings-in-dexcom-inc-dxcm/1760528.html.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with Analyst Ratings Network's FREE daily email newsletter.